Volume 73, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Therapeutic failure in the treatment of cutaneous leishmaniasis (CL) occurs in 5% of patients infected by . This study evaluates the use of topically applied granulocyte macrophage colony-stimulating factor (GM-CSF) combined with the standard dose of antimony to treat refractory cases of CL. Five patients who had received three courses or more of antimony were enrolled in an open-label clinical trial. One to 2 mL of the GM-CSF solution (10 μg/mL in 0.9% saline) was reapplied topically, and dressings were changed three times per week for 3 weeks, associated with standard parenteral antimony (20 mg kg day for 20 days). All the patients healed their CL ulcers; 3 healed within 50 days (21, 27, and 44 days) and 2 in 118 and 120 days after beginning therapy. There were no side effects. This study shows that combined topically applied GM-CSF and antimony can be effective and well tolerated in the treatment of relapsed CL.


Article metrics loading...

Loading full text...

Full text loading...



  1. Modabber F, 1987. The Leishmaniases. Maurice J, Pearce AM, eds. Tropical Diseases Research: A Global Partnership. Eight Programme Report. Geneva: World Health Organization, 99–112.
  2. Bittencourt AL, Barral-Netto M, 1995. Leishmaniasis. Doerr W, Seifert G, eds. Tropical Pathology. Heidelberg: Springer, 597–651.
  3. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic and chemotherapeutic development in the last 10 years. Clin Infect Dis Apr 24 : 684–703.
  4. Barral-Netto M, Machado P, Bittencourt AL, Barral A, 1997. Recent advances in the pathophisiology and treatment of human cutaneous leishmaniasis. Curr Opin Dermatol 4 : 51–58.
  5. Sampaio SA, Castro RM, Dilon NL, Martins JE, 1971. Treatment of mucocutaneous (American) leishmaniasis with amphetericin B: report of 70 cases. Int J Dermatol 10 : 179–181.
  6. Soto-Mancipe J, Grogl M, Berman JD, 1993. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16 : 417–425.
  7. Koff AB, Rosen T, 1994. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31 : 693–708.
  8. Lieschke GL, Burgess AW, 1992. Granulocyte colony-stimulating factor and granulocyte-macrophage-colony stimulating factor. N Engl J Med 327 : 99–106.
  9. Jones TC, 1996. The effect of granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on macrophage function in microbial disease. Med Oncol 13 : 141–147.
  10. Ho JL, Reed SG, Wick EA, Giordano M, 1990. Granulocyte-macrophage and macrophage colony stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 162 : 224–230.
  11. Al-Zamel F, Al-Shammary FJ, El-Shewemi S, 1996. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte-macrophage colony-stimulating factor. Zentralbl Bakteriol. 285 : 92–105.
  12. Jones TC, 1993. The effects of rhGM-CSF on macrophage function. Eur J Cancer 29 (Suppl 3): 10–13.
  13. Marques da Costa R, Aniceto C, Jesus FM, Mendes M, 1994. Quick healing of leg ulcers after molgramostim. Lancet 344 : 481–482.
  14. Kurzrock R, Talpaz M, Gutterman JU, 1992. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 93 : 41–48.
  15. Jaschke E, Zabernigg A, Gattinger C, 1999. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38 : 380–386.
  16. Robson MC, Phillips TJ, Falanga V, Odenheimer DJ, Parish LC, Jensen JL, Steed DL, 2001. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9 : 347–352.
  17. Almeida RP, D’Oliveira A Jr, Machado P, Bacellar O, Ko AI, Ribeiro de Jesus A, Mobashery N, Santos JB, Carvalho EM, 1999. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 180 : 1735–1737.
  18. Santos JB, de Jesus AR, Machado PR, Magalhães A, Salgado S, Carvalho EM, Almeida RP, 2004. Recombinant human GM-CSF applied topically in low doses plus antimony enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind study. J Infect Dis 190 : 1793–1796.
  19. Robson M, Kucukcelebi A, Carp SS, 1994. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 13 : 41–46.
  20. Kaplan G, Walsch G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R, 1992. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony–stimulating factor. Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175 : 1717–1728.
  21. Kucukcelebi A, Carp SS, Haward PG, 1992. Granulocyte-macrophage colony-stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination. Wounds 4 : 241–247.
  22. Doherty TM, Coffman RL, 1993. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major. J Immunol 150 : 5476–5483.

Data & Media loading...

  • Received : 02 Sep 2004
  • Accepted : 26 Feb 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error